National Peroxide board defers results meet for FY26

What is happening

National Peroxide Limited has deferred a Board meeting that was scheduled for August 03, 2026. The meeting was planned to consider and approve a set of financial results and statements, including revised audited numbers for the year ended March 31, 2026 and unaudited results for the quarter ended June 30, 2026. The company cited unavoidable circumstances for the deferment. The update keeps the stock on the radar because the agenda includes both revisions to audited accounts and the first quarterly update of FY2027 (April-June 2026 quarter).

For investors, deferred result timelines matter because they affect when audited statements, quarterly performance, and corporate actions can be evaluated against earlier disclosures. In National Peroxide’s case, the market has also been tracking a final dividend recommendation for FY2026 and reported profitability versus FY2025.

Items on the board agenda

The company stated that the primary agenda for the deferred meeting was to consider and approve three items. These include revised audited financial results for the quarter and financial year ended March 31, 2026, revised audited financial statements for the financial year ended March 31, 2026, and unaudited financial results for the quarter ended June 30, 2026. The agenda indicates that the company is not only finalising the June 2026 quarter update but also re-working FY2026 audited numbers.

The mention of “revised” audited results and statements is significant because it implies updates to numbers that were previously audited and released. The company’s communication in the provided text does not specify the nature of the revision, the line items impacted, or the revised meeting date. Investors typically monitor such revisions closely because they can change the interpretation of performance, cash flows, or balance sheet strength.

Board meeting deferred on August 03, 2026

National Peroxide said the Board meeting scheduled for August 03, 2026 was deferred due to unavoidable circumstances. The meeting was intended to approve unaudited results, described in the context as Q1FY26 unaudited results, and it also carried the wider agenda of revised FY2026 audited approvals. In Indian financial reporting, the fiscal year is April to March, which is also stated in the provided data.

Because the quarter ended June 30, 2026 corresponds to Q1 of FY2027 (FY27), investors should read the deferment as a delay in the April to June 2026 financial update. Separately, the deferment also delays visibility on any changes that may come through revised FY2026 audited numbers.

A previous deferment in January 2026

The supplied context also references an earlier deferral. It states that a Board meeting originally scheduled for January 28, 2026 was deferred, and that meeting was intended to approve unaudited financial results for the quarter and nine months ended December 31, 2025. That deferment was also attributed to unavoidable circumstances.

Taken together, the two deferrals suggest that investors may have to track revised schedules and subsequent disclosures carefully to avoid missing updated filing timelines. The text provided does not mention the eventual date on which the January 2026 deferred meeting was held, nor does it specify the revised date for the August 2026 meeting.

FY2026 performance as disclosed in earlier updates

Multiple FY2026 figures appear in the supplied material. One disclosure states that total income for FY2026 was ₹295.68 crore and profit after tax (PAT) was ₹11.04 crore, compared with a loss of ₹2.25 crore in FY2025. It also reports earnings per share (EPS) of ₹19.20 (basic and diluted) for FY2026, compared with a loss per share of ₹3.91 in FY2025.

Another FY2026 summary in the provided text states operational revenue of ₹289.71 crore for the full year ended March 2026, with PAT of ₹11.04 crore, against ₹286.87 crore revenue and a ₹2.25 crore net loss in FY2025. The same summary notes equity capital of ₹5.75 crore and shareholders’ reserves of ₹356.27 crore, translating into a book value of ₹630 per share (face value ₹10).

Quarter and nine-month FY2026 snapshot

The material also includes quarterly and nine-month figures for FY2026. It reports Q3 revenue from operations of ₹69.087 crore and nine-month revenue of ₹204.0285 crore. For profitability, it reports Q3 PAT of ₹1.8323 crore and nine-month PAT of ₹3.1085 crore. An exceptional item of ₹0.5815 crore was recognised in Q3 due to past service costs.

Separately, standalone quarterly numbers for the quarter ended March 2026 are presented as net sales of ₹85.68 crore versus ₹73.70 crore in March 2025. The same standalone snapshot reports quarterly net profit of ₹7.93 crore in March 2026 versus ₹6.49 crore in March 2025, and EBITDA of ₹16.26 crore versus ₹2.35 crore. EPS for the March 2026 quarter is shown as ₹13.80 versus ₹11.29 for March 2025.

Final dividend recommendation and board date reference

National Peroxide is also linked in the provided text to a corporate action calendar entry dated April 30, 2026 for “Audited Results & Final Dividend.” The board recommended a final dividend of ₹7 per equity share for FY2026, equivalent to 70% of face value, subject to shareholder approval. The date is relevant because it anchors when FY2026 audited results and the dividend recommendation were communicated in the material.

Any subsequent revisions to audited FY2026 results, as indicated by the deferred August 2026 agenda, will likely be tracked against what was previously released around April 30, 2026.

Key facts table (normalised to ₹ crore)

Another dataset in the material shows different FY numbers

The supplied content also contains a separate five-year table labelled “All values INR Millions,” where FY2026 sales/revenue is shown as INR 268 million, which normalises to ₹26.8 crore. In the same table, operating income for FY2026 is INR 111 million (₹11.1 crore), consolidated net income is INR 107 million (₹10.7 crore), and basic EPS is 18.60. The same dataset shows FY2025 sales/revenue of INR 201 million (₹20.1 crore) and EPS of 18.36.

These figures differ materially from the ₹295.68 crore total income and ₹289.71 crore operational revenue mentioned elsewhere in the provided text. The supplied material does not explain why the datasets diverge, whether they reflect different reporting scopes, or whether one dataset is incomplete. Because the August 2026 agenda includes “revised” audited results and statements for FY2026, investors may focus on future disclosures for clarity and reconciliation.

What investors can track next

The immediate next trigger is a rescheduled date for the deferred August 03, 2026 Board meeting and the release of unaudited results for the quarter ended June 30, 2026. The same meeting is expected to address revised audited results and revised audited financial statements for the year ended March 31, 2026. Investors may also track any further communication on the FY2026 final dividend of ₹7 per share, which remains subject to shareholder approval as stated.

Until updated filings are released, the most concrete reference points in the supplied text remain the FY2026 total income of ₹295.68 crore, PAT of ₹11.04 crore, and the previously announced final dividend recommendation, alongside the reported quarterly and nine-month FY2026 operating snapshots.